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Abstract
Purpose: Bolus electron conformal therapy (BECT) is a clinically useful, well- 
documented, and available technology. The addition of intensity modulation (IM) 
to BECT reduces volumes of high dose and dose spread in the planning tar-
get volume (PTV). This paper demonstrates new techniques for a process that 
should be suitable for planning and delivering IM- BECT using passive radio-
therapy intensity modulation for electrons (PRIME) devices.
Methods: The IM- BECT planning and delivery process is an addition to the 
BECT process that includes intensity modulator design, fabrication, and qual-
ity assurance. The intensity modulator (PRIME device) is a hexagonal matrix of 
small island blocks (tungsten pins of varying diameter) placed inside the patient 
beam- defining collimator (cutout). Its design process determines a desirable 
intensity- modulated electron beam during the planning process, then determines 
the island block configuration to deliver that intensity distribution (segmenta-
tion). The intensity modulator is fabricated and quality assurance performed at 
the factory (.decimal, LLC, Sanford, FL). Clinical quality assurance consists of 
measuring a fluence distribution in a plane perpendicular to the beam in a water 
or water- equivalent phantom. This IM- BECT process is described and demon-
strated for two sites, postmastectomy chest wall and temple. Dose plans, inten-
sity distributions, fabricated intensity modulators, and quality assurance results 
are presented.
Results: IM- BECT plans showed improved D90- 10 over BECT plans, 6.4% versus 
7.3% and 8.4% versus 11.0% for the postmastectomy chest wall and temple, re-
spectively. Their intensity modulators utilized 61 (single diameter) and 246 (five 
diameters) tungsten pins, respectively. Dose comparisons for clinical quality as-
surance showed that for doses greater than 10%, measured agreed with cal-
culated dose within 3% or 0.3 cm distance- to- agreement (DTA) for 99.9% and 
100% of points, respectively.
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1 |  INTRODUCTION
To date three types of electron conformal therapy (ECT) 
have been studied, bolus ECT (BECT), segmented- 
field ECT, and modulated electron radiation therapy 
(MERT).1 Each has advantages and disadvantages 
compared with the others; however, only BECT tech-
nology is widely available in today's clinic. In BECT, a 
variable thickness bolus abutting the patient surface 
is used to modulate laterally the therapeutic range, for 
example, R90, so that the 90% dose surface conforms 
to (circumscribes) the patient planning target volume 
(PTV). BECT offers the potential for lower whole body 
dose, reducing secondary cancer risks, and equal or 
lower dose to nearby critical structures, reducing nor-
mal tissue complications, as compared to that of inten-
sity modulated x- ray therapy (IMXT).
Historically, electrons have been an important mo-
dality for (1) the treatment of skin, lip, head, and neck 
tumors, (2) boost doses to superficial lymph nodes, 
and (3) postmastectomy chest wall irradiation.2– 5 
Since the onset of 3D treatment planning, BECT has 
been shown useful for posterior chest wall6– 8; post-
mastectomy chest wall7,9– 11; ear, parotid, and buccal 
mucosa7,12; nose13; and extremities (hand and foot).8 
As a result, BECT is currently available from two 
companies that provide bolus design software, which 
integrate with one's treatment planning system,8,14 
and bolus fabrication methods (milled or printed).6,8
The typical BECT treatment and delivery process 
consists of patient immobilization, CT scanning, PTV and 
normal tissue delineation, beam design, bolus design, 
dose calculation, bolus fabrication, and quality assur-
ance.6 Bolus design is typically an iterative optimization 
process.8,14 Physical quality assurance following fabri-
cation can be made by bolus thickness measurement 
at multiple off- axis locations. Clinical, dosimetric quality 
assurance can be made using a repeat CT scan from a 
CT simulator or pre- treatment cone beam CT to perform 
a patient dose calculation with bolus in place.6,13
Clinical experience has demonstrated that in some 
cases, the upstream bolus surface is sufficiently irregular 
to cause undesirable dose heterogeneities in the PTV, that 
is, volumes of increased dose (hot spots) and decreased 
dose (cold spots). However, Kudchadker et al.7 showed 
that the introduction of modest intensity modulation (70%– 
100%) across the beam, followed by moderate redesign of 
the bolus, can significantly reduce PTV dose heterogene-
ity while maintaining a dose distribution conformal to the 
PTV. Hence, intensity modulated BECT, that is, IM- BECT, 
can conform the therapeutic dose surface (e.g., 90%) to 
the distal PTV surface, while producing a reasonably uni-
form dose in the PTV (≈10%– 15% dose spread).
Recently, Hogstrom et al.15 developed a simple, po-
tentially economical method for design and fabrication of 
a passive radiotherapy intensity modulator for electrons 
(PRIME) device,16 analogous to the utilization of x- ray com-
pensators for IMXT prior to the widespread availability of 
x- ray multi- leaf collimators (MLCs).17,18 The objective of this 
paper is to describe a process that should be suitable for 
planning and delivery of IM- BECT. The process, detailed 
and demonstrated for two patient sites, includes adding 
techniques for design, fabrication, and quality assurance of 
the intensity modulator19,20 to the current BECT process.6
2 |  METHODS
Methods for planning and delivering IM- BECT are 
demonstrated using data from two patients previously 
treated using BECT. For each patient, treatment plan-
ning was done using research versions of a BECT 
bolus design system in which the ability to utilize inten-
sity modulators was added. The intensity modulators 
(PRIME devices) resulting from the treatment plans 
were fabricated, then the process of clinical quality 
assurance of the fabricated intensity modulators was 
demonstrated by comparing dose calculations with 
measurements beneath the intensity modulators in a 
water phantom. Planning and delivery techniques, that 
is, bolus and intensity modulator design, patient dose 
calculation, fabrication of intensity modulator, and qual-
ity assurance, are presented.
2.1 | Patient data
Two anonymized patient CT data sets (HIPAA com-
pliant) were selected for two sites, postmastectomy 
chest wall and temple. Each patient had been treated 
Conclusion: These results demonstrated the feasibility of translating IM- BECT 
to the clinic using the techniques presented for treatment planning, intensity 
modulator design and fabrication, and quality assurance processes.
K E Y W O R D S
bolus electron conformal therapy, electron beams, intensity modulation
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previously with BECT. Chest wall and head and neck 
patients were selected because such patients have 
shown moderately and significantly improved PTV 
dose homogeneity when using IM- BECT as opposed 
to BECT (Kudchadker et al.,7 Doiron21). This study used 
the planning target volumes (PTVs), normal tissues, 
and structures previously contoured by radiation on-
cologists and medical dosimetrists (cf. Figure 1).
2.2 | Treatment planning
The patient plans for this study were developed using 
the Pinnacle3 treatment planning system (Philips) and 
research versions of the p.d bolus design system22 
(.decimal, LLC). The beam geometry (gantry, couch, 
and collimator angles; source to surface distance, SSD; 
and table and isocenter locations), block aperture, and 
beam energy for each patient's previous BECT treat-
ment, and the PTV outlines, structure outlines, and CT 
data for each patient were inputted from Pinnacle3 into 
the p.d software using DICOM transfer. For both patients 
the selected beam energy was 16 MeV (R90 = 5.0 cm).
The p.d software system designed the bolus and in-
tensity modulator and calculated the dose distribution 
for each patient IM- BECT plan. This process can be 
done in approximately 2 hours by a treatment planner 
competent with the IM- BECT planning process and p.d 
software. Details of this treatment planning process 
and how it differs from a BECT treatment planning pro-
cess are presented as follows.
2.2.1 | Initial bolus design
For each patient, a conformal bolus was designed 
using the clinical version (v5.1) of p.d.22 The bolus was 
designed such that the 90% dose surface conformed 
to (circumscribed) the distal PTV surface. The design 
process used a sequence of operators that created, 
modified, and extended the bolus. The Create (physical 
depth), Isodose Shift, Smooth, and Height Extension 
operators were those of Low et al.,14 and the speci-
fied shift operator shaved or added a specified uniform 
thickness to the bolus. The operators were used in se-
quences which best achieved the treatment planning 
goals, namely that the 90% isodose surface circum-
scribed the PTV. The Truncate operator removed up-
stream bolus surface outside the field to reduce bolus 
weight, having no impact on the dose distribution. The 
sequences of operators used to design the initial pa-
tient bolus for each patient are listed in Table 1.
2.2.2 | Initial intensity modulator design
After completing the initial bolus design, the intensity 
modulation operator was applied to create greater 
dose homogeneity within the patient by reducing dose 
greater than 100% (hot spots, as dose typically is pre-
scribed to 90%). These IM- BECT treatment plans were 
created in a research version of p.d, which included an 
additional intensity modulation operator, as described 
by Hilliard.20 The intensity modulation operator requires 
the user to choose a limit to the maximum and mini-
mum intensity reduction factors (IRFs). The program 
then designs an intensity map (IRF versus off- axis po-
sition) based on the dose distribution resulting from the 
initial bolus design.
Because of a small interdependence of the bolus 
and intensity modulator,7 to achieve better patient plans 
the bolus requires reoptimization following application 
of the intensity modulation operator. The research ver-
sion of p.d used for the initial intensity modulator design 
and fabrication did not allow for bolus reoptimization, 
but was sufficient for early bolus fabrication and QA 
measurements. A subsequent research version of p.d, 
which included bolus reoptimization, was used to gen-
erate the final dose distributions used to evaluate pa-
tient plans. Although the two research versions differed 
slightly, differences in their designed intensity modula-
tors were clinically insignificant (<1%).
The sequences of operators used to design the fab-
ricated intensity modulators are shown in Table 1. The 
F I G U R E  1  3D rendering of the 
postmastectomy chest wall (left) and 
temple (right) patient data used in current 
demonstration. The renderings show 
the skin surface, planning target volume 
(aqua), electron collimating insert (yellow), 
and electron beam (gray)
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sequences of operators used for the final patient plans, 
which includes bolus reoptimization are shown Table 2. 
Bolus reoptimization was not required for the temple 
patient.
Modification of pencil beam weights
The intensity modulation operator modifies the weight 
of each pencil beam by looking at the maximum dose 
along each ray line from the beam's virtual electron 
source (assumed 100 cm from isocenter) through the 
center of each pencil beam, which falls a specified 
margin (0.5 cm) inside the edge of the PTV. The pencil 




 is modified so 
that
where
where Dmax(i, j) is the maximum percent dose along the 
(i, j) pencil beam ray- line, and the intensity reduction 
factor (IRF) was limited to the range from 0.8 to 1.0. 
Pencil beam weights for pencil beams with ray- lines 
outside of the specified margin were determined using 
the same method Low et al.14 used for bolus height 
extension.
Segmentation of pencil beam weights into island 
blocks
Similar to an x- ray intensity modulated field being seg-
mented into an MLC leaf sequence, the intensity map of 
the “new” beam weights was segmented into an island 
block pattern that closely achieved that intensity map. 
The segmentation process was based on an algorithm 
developed by Chambers.19 It takes the initial island block 
pattern, determined using the method described below, 
then calculates the underlying intensity pattern using a 
pencil beam algorithm.23 After comparing the calculated 
with the desired intensity pattern, island block diameters 
are modified. This process, which iterates until results 
meet an optimization criteria, is shown schematically in 
Figure 2.
In the current study, only the initial step in the cham-
bers optimization algorithm was used. Island blocks were 
placed on a 0.6- cm hexagonal grid (specified at 93.5 cm 











(1b)IRF = 1.000 for Dmax (i, j) < 100%,
(1c)
IRF = 100%∕Dmax (i, j) for 100%≤Dmax (i, j) ≤ 80
−1 %,
(1d)IRF = 0.800 for Dmax (i, j) > 80%
−1,
Post- mastectomy chest wall 
patient Temple patient
1. Create (90%, 0.7 cm)
2. Smooth (2,1)
3. Isodose Shift (0.5 cm)
4. Smooth (2,1)
5. Isodose Shift (0.5 cm)
6. Smooth (2,1)
7. Truncate
8. Specified Shift (−0.1 cm 
BECT, −0.3 cm IM- BECT)
9. Intensity Modulation
1. Create (90%, 0.7 cm)
2. Smooth (2,1)
3. Isodose Shift (0.5 cm)
4. Smooth (2,1)
5. Isodose Shift (0.5 cm)
6. Smooth (2,1)
7. Truncate
8. Specified Shift (−0.2 cm BECT, −0.4 cm IM- BECT)
9. Intensity Modulation
The resulting intensity modulators were fabricated for QA measurements. The BECT operator sequence 
(un- bolded steps) was followed by the intensity modulation sequence (bolded step). The Create operator 
input parameters are the percent dose (90%) being conformed to the distal PTV and the distance inside 
the PTV edge (0.7 cm) in which the bolus is created based on physical depth; the Smooth operator input 
parameters are a multiplier (2) in the exponent of a Gaussian function and a multiplier (1) of a 1.5- cm 
radial distance over which the smoothing of the bolus height occurs; the Isodose Shift operator input 
parameter is the distance inside the PTV edge (0.5 cm) in which the bolus thickness is increased or 
decreased to shift the depth of the 90% dose surface within the patient; and the Specified Shift operator 
input parameter (−0.1 or −0.2 cm) is the thickness subtracted from the entire proximal bolus surface. 
Truncate minimizes the bolus mass by reducing the flat, upstream bolus surface outside the treatment 
field, having no impact on the dose distribution.
TA B L E  1  Sequence of p.d operators 
(parameters in parenthesis) used to 
design a bolus and intensity modulator for 
each patient22
TA B L E  2  Sequences of p.d operators (parameters in 
parenthesis) used for comparing BECT and IM- BECT patient plans. 
BECT plans used the operator sequence (non- bolded steps); 
IM- BECT plans used the same BECT sequence plus the intensity 
modulation and bolus reoptimization sequence (bolded steps)
Post- mastectomy chest wall 
patient Temple patient
 1. Create (90%, 0.5 cm)
 2. Smooth (2,1)
 3. Isodose Shift (0.5 cm)
 4. Smooth (2,1)
 5. Isodose Shift (0.5 cm)
 6. Smooth (2,1)
 7. Truncate
 8. Specified Shift (−0.1 cm)
 9. Intensity Modulation
 10. Isodose Shift (0.5 cm)
 11. Smooth (2,1)
 12. Specified Shift (−0.1 cm)
1. Create (90%, 0.7 cm)
2. Smooth (2,1)
3. Isodose Shift (0.5 cm)
4. Smooth (2,1)
5. Isodose Shift (0.5 cm)
6. Smooth (2,1)
7. Truncate
8. Specified Shift (−0.2 cm)
9. Intensity Modulation
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hexagonal grid the algorithm first calculated the island 
block diameter d based on fraction of area blocked using15
where r is the distance separating the hexagonally packed 
circular island blocks of diameter d, and IRF is the inten-
sity reduction factor, which equals the ratio of the desired 
underlying intensity to that in the absence of the intensity 




. Then, the algorithm selected 
an island block diameter closest from a set of available 
tungsten island block diameters (cf. Table 3). The result-
ing island block patterns were sent to the p.d bolus design 
system for the final dose calculation and to .decimal for 
fabrication of the intensity modulator.
2.2.3 | Dose calculation using the pencil 
beam redefinition algorithm (PBRA)
For its electron beam dose calculations p.d bolus design 
software utilizes the pencil beam redefinition algorithm 
(PBRA), developed originally by Shiu and Hogstrom24 
and improved by Boyd et al.25 to include a polyener-
getic, incident electron beam. Dose at each point (x, y, 
z) is the sum of the electron beam component (De) and 
the background x- ray dose component (DX), that is,
where the x- ray dose calculation uses an empirical, data 
based model described by Shiu.26 The electron dose 
calculation transports the phase space of the electron 
pencil beams at z to pencil beams at z + Δz modelling 
collisional energy loss, multiple Coulomb scattering, and 
beam divergence.
The PBRA was extensively validated by Boyd et al.27 
using a measured data set by Boyd et al.28 for a number 
of patient- like geometries and using Monte Carlo calcu-
lations for multiple patient sites.29 The PBRA was also 
validated in anthropomorphic phantoms for use with 
BECT by Carver et al.30
Changes to the PBRA for intensity modulators
For dose calculations with the passive intensity mod-
ulators containing island blocks, used in this study, 
three modifications were made to the PBRA: (1) re-
ducing the energy of the beam to decrease R90 by 
0.1 cm, which accounts for energy loss in the 1.27- 
cm thick machinable foam (ρ = 0.096 g cm−3) con-
taining the island blocks, (2) increasing the initial 
angular spread x by 50% to account for additional 
scatter in the machinable foam, and (3) modelling the 
effect of the island blocks removing electrons from 
the beam. Details of the former two are described by 
Hilliard.20
The third modification of the PBRA code ac-
counted for the reduction in electron fluence 
reaching the bolus surface due to the island blocks 
embedded in the intensity modulator's machinable 
foam. It was assumed that all electrons incident on 
the top surface of the island blocks are removed 
from the beam. This required modifying only the 
first step of the PBRA, which transports electron 
fluence from the plane of the collimator to the sur-
face of the bolus (or patient). Each circular island 









(3)D (x, y , z) = De (x, y , z) + DX (x, y , z) ,
F I G U R E  2  Workflow for the electron intensity modulator generator software. An initial block matrix using equation (2) is generated 
and tested using pre- established criteria. Points of failure are improved iteratively until criteria are met or minimized. Abbreviations: PBA is 
pencil beam algorithm; BM is Block Matrix
d (cm) 0.158 0.223 0.273 0.315 0.352 0.386 0.417 0.473
IRF (%) 93.7 87.5 81.2 75.0 68.8 62.5 56.2 43.6
TA B L E  3  Available tungsten island 
block diameters d and corresponding IRF 
values when used with 0.6 cm hexagonal 
spacing r
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block was modelled as a square pencil beam of 
equal area, whose electrons were transported to 
the surface of the bolus (or patient) with negative 
fluence.
This concept, illustrated in Figure 3, determines the 
fluence at the starting pixel for the first pencil beam 
along each (i, j) ray line, which is given by
where l
i,j
 is the fluence that would be contributed by 
electrons striking the lth block in its absence to the (i, j) 
pencil beams. This approximation ignored (1) electrons 
scattered into or out of the sides of the island blocks, 
that is, assumes perfect collimation, and (2) any 
changes to the bremsstrahlung dose caused by the is-
land blocks.
2.3 | Intensity modulator fabrication
Once the intensity modulators (PRIME devices) 
were designed, they were fabricated by .decimal 
using the following procedure. First, a standard 
patient- specific 1.48- cm thick copper cutout was 
machined. Second, a 1.27- cm thick machinable 
foam insert matching the shape of the copper cut-
out was machined, and holes with axes following 
diverging rays from the virtual source were drilled 
0.9 cm deep with the appropriate diameter to 
match the designed island block at the locations 
on the hexagonal grid having island blocks. Third, 
the milled machinable foam block was press- fitted 
into the copper cutout. Fourth, the appropriate 
diameter 0.6- cm long tungsten pin was manually 
inserted into each hole, completing the device. 
The entire process took approximately 2 hours, al-
though some manual steps could be automated in 
the future.
2.4 | Intensity modulator 
quality assurance
IM- BECT requires at least three patient- specific de-
vices: wax bolus, electron cutout, and intensity modu-
lator (occasionally skin collimation, internal collimation, 
or eye blocks are also used). Wax bolus quality as-
surance (QA) is the same for IM- BECT as for BECT, 
which presently, is typically achieved by factory meas-
urements and clinical acquisition of either a simulation 
CT scan with bolus1,6 or pre- treatment cone- beam CT 
scan.13 Alternatively, the clinical QA could be a CT scan 
of the bolus. This section focuses on quality assurance 
for the intensity modulator, which by its nature also pro-
vides quality assurance of the collimating cutout that 
contains the intensity modulator.
2.4.1 | Factory quality assurance
The objective of factory quality assurance was to ensure 
that the correct diameter island blocks were inserted into 
the machinable foam substrate at the correct locations 
on the hexagonal grid. This was achieved by capturing 
an image of the intensity modulator (cf. Figure 4) using 
an optical scanner. A software program then used lines 
scored on the copper cutout that demarcate the beam 
orthogonal axes to determine planned locations of is-
land blocks on the specified hexagonal grid. Second, 
the software validated the presence or absence of an 
island block. Third, the proper island block diameter was 
manually verified. Following factory quality assurance, 
the copper cutout- intensity modulator was shipped to 
Mary Bird Perkins Cancer Center (MBPCC).
2.4.2 | Clinical quality assurance
The clinical quality assurance (QA) process mimics 
that used for x- ray intensity modulation (generated by 
either a metal compensator or multi- leaf collimator) in 














F I G U R E  3  Schematic drawing 
showing how the PBRA code incorporated 
island blocks into the dose calculation for 
intensity modulated electron beams using 
the passive intensity modulators with 
island blocks
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a plane perpendicular to beam central axis. In the pre-
sent study, measurements were made at 0.5 and 2.0- 
cm depths in a water phantom at 100- cm SSD using a 
scanning diode. These measurements were then com-
pared with the PBRA calculated off- axis dose distribu-
tions generated in p.d after replacing the patient and 
bolus with a water phantom. Our objective was to verify 
that the patient- specific intensity modulator delivered a 
relative fluence (dose) distribution within 3% or 0.3 cm 
of that calculated by the PBRA.
Calculation of dose distributions downstream of 
patient intensity modulators
Relative dose (fluence) distributions were calculated 
using a research version of p.d. The dose was normal-
ized such that 100% equaled the “given dose” without 
the intensity modulator. “Given dose” is the maximum 
central axis dose in water, Dmax at R100, for the patient's 
effective field size (rectangular field with minimum area 
that circumscribes the irregular patient field), energy, 
and SSD. SSD was the distance from a point 100 cm 
upstream of isocenter to the bolus surface on central 
axis.
For comparison to measured dose distributions, the 
dose distributions were calculated in a water phan-
tom with the patient intensity modulator (device cutout 
and island block pattern) for each patient. The dose 
was then transferred from p.d to the Pinnacle3 (v9.10 
Philips) treatment planning system so that planar dose 
distributions could be exported to a laptop computer 
using MATLAB software (R2016, MathWorks). The 
planar dose ASCII files exported from Pinnacle3 con-
tained a grid of calculated dose with pixel sizes of 
0.1 cm.
Dose measurement downstream of patient intensity 
modulators
Off- axis profiles were measured using an electron 
diode in a Blue Phantom2 (IBA Dosimetry) 3D scanning 
system; a CC13 ion chamber was used as the refer-
ence detector. The detectors were connected to a beam 
scanning common control unit (CCU), which contained 
two internal electrometers. The water phantom servo 
and CCU were controlled using the OmniPro- Accept 
scanning software (v7, IBA Dosimetry). The water sur-
face was set to 100- cm SSD. Planar dose measure-
ments were made at depths of 0.5 and 2.0 cm in water. 
Details of phantom setup are standard and have been 
reported by Hilliard.20
All measurements were performed on an Elekta 
Infinity accelerator, whose commissioned central- 
axis depth doses were used by the PBRA. Measured 
doses were normalized in the identical manner as was 
the calculated dose with 100% equaling the “given 
dose”.
Methods for comparing calculated and measured 
dose distributions
The calculated and measured planar dose distributions 
were compared using isodose plots at the two measured 
depths (0.5 cm and 2.0 cm) for the intensity modulator 
of each of the two IM- BECT treatment plans. Results at 
2.0 cm are recommended for clinical QA and are pre-
sented here; results at 0.5 cm were similar and are reported 
by Hilliard.20 The percent dose difference and distance to 
agreement (DTA) between the calculated and measured 
distributions were calculated, where the DTA is defined as 
the distance from the point being examined and the closest 
point where the dose distributions have the same value. All 
points receiving at least 10% of the maximum dose were 
included in the percent dose difference/DTA analysis.
3 |  RESULTS
3.1 | Patient treatment plans
The chest wall patient's IM- BECT dose distribution is 
plotted for selected CT planes in Figure 5a– c. The sag-
ittal plane demonstrates PTV coverage with respect to 
the heart and lung; the two transverse planes further 
demonstrate PTV coverage in planes through the heart 
and through the lungs. Figure 5d compares PTV, lung, 
and heart dose volume histograms (DVHs) for the IM- 
BECT and BECT plans. DVHs were normalized such 
that the V95 for the PTVs match between the BECT and 
IM- BECT plans. The IM- BECT PTV DVH shows dose 
homogeneity improved from that of the BECT plan; the 
F I G U R E  4  Optical scan of temple intensity modulator used 
for factory quality assurance. Shown is the custom copper cutout 
containing tungsten island blocks inserted into the machinable 
foam
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D90- 10 is reduced from 7.3% to 6.4%, and the maximum 
PTV dose is reduced from 103.6% to 101.4%. These 
are due to reducing the intensity inferiorly and laterally.
The temple patient's IM- BECT dose distribution is 
plotted for selected CT planes in Figure 6a– c. The sag-
ittal plane demonstrates PTV coverage with respect to 
the temple and brain; the two transverse planes fur-
ther demonstrate PTV coverage in planes through the 
right eye and brain. Figure 6d compares PTV DVHs for 
the IM- BECT and BECT plans. DVHs were normalized 
such that the V95 for the PTVs match between the BECT 
and IM- BECT plans. The IM- BECT DVH shows dose 
homogeneity improved from that of the BECT plan; the 
D90- 10 is reduced from 11.0% to 8.4%, and the max-
imum PTV dose is reduced from 118.6% to 109.8%. 
These are due to reducing the intensity over the thinner 
regions of the bolus, which had underlying hot spots 
without intensity modulation.
3.2 | Intensity modulator design and 
fabrication
The isointensity distribution determined in the treatment 
planning process for the chest wall patient is mapped in 
Figure 7a. The range of intensity modulation was small 
in this case (0.94– 1.00). It was mostly needed in the 
vicinity of the medial, inferior border of the field, due to 
angled incidence and shorter SSD of the patient there. 
This isointensity distribution was used to determine the 
island block distribution, which is shown in Figure 7b. 
The resulting isointensity distribution created by the 
island blocks is illustrated in Figure 7c by plotting the 
PBA- calculated relative fluence distribution at a 0.5- cm 
depth in a water phantom at 105 cm SSD. A photo-
graph of the intensity modulator fabricated by .decimal 
is shown in Figure 7d. This intensity modulator required 
only 61 island blocks (all 0.158 cm diameter) placed at 
the specified locations on a 0.6- cm hexagonal grid.
Similarly, the isointensity distribution determined in 
the treatment planning process for the temple patient is 
mapped in Figure 8a. The range of intensity modulation 
was moderate in this case (0.82– 1.00). It was mostly 
needed in the inferior portion of the anterolateral PTV 
region where the bolus was thinnest. Here, in- scatter 
from the surrounding thicker portions of the bolus, 
which created considerable variability (gradients) of 
the bolus surface, resulted in hot spots. This isointen-
sity distribution was used to determine the island block 
distribution, which is shown in Figure 8b. The resulting 
F I G U R E  5  Chest wall patient CT 
planes showing the PTV (teal) and 
isodose lines (90% is yellow) for IM- BECT 
treatment plan. The bolus is shaded blue. 
(a) Sagittal plane containing the central 
axis of the beam; dashed lines indicate 
positions of axial planes. Axial planes are 
(b) 3.5 cm superior (lung) and (c) 3.5 cm 
inferior (heart) to the central axis of the 
beam. (d) PTV, heart, right lung, and 
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isointensity distribution created by the island blocks is 
illustrated in Figure 8c by plotting the PBA- calculated 
relative fluence distribution at a 0.5- cm depth in a water 
phantom at 105 cm SSD. A photograph of the intensity 
modulator fabricated by .decimal is shown in Figure 8d. 
This intensity modulator required 246 island blocks (1 
F I G U R E  6  Temple patient CT planes 
showing the PTV (teal) and isodose lines 
(90% is yellow) for IM- BECT treatment 
plan. The bolus is shaded blue. (a) 
Sagittal plane containing the central 
axis of the beam; dashed lines indicate 
positions of axial planes. Axial planes are 
(b) 3.0 cm inferior (R eye and brain) and 
(c) 3.0 cm superior (brain) to the central 
axis of the beam. (d) PTV, right eye, right 
lens, and right parotid DVHs for IM- BECT 
and BECT treatment plans
F I G U R E  7  (a) Chest wall objective 
isointensity map as calculated by p.d 
(b) Pin pattern design resulting from 
segmentation of objective intensity 
map as described in Section 2.2.2. (c) 
PBA- calculated intensity map based on 
pin pattern. (d) Photograph of intensity 
modulator fabricated for the chest wall site 
IM- BECT treatment plan. (- X is medial; - Y 
is inferior)
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at 0.352, 1 at 0.315, 7 at 0.273, 17 at 0.223, and 220 at 
0.158 cm diameter) placed at the specified locations on 
a 0.6- cm hexagonal grid.
3.3 | Quality assurance of intensity 
modulator and bolus
Quality assurance of the intensity modulator at both the 
factory and clinical site occurred. Factory quality as-
surance used optical scanned images (similar to pho-
tographs in Figures 7d and 8d) to automatically validate 
pins were inserted at the desired locations on a hex-
agonal grid. Pin diameters were verified manually.
Clinical quality assurance was done by measuring 
the relative dose distribution at a 2.0- cm depth in a 
water phantom underlying the intensity modulator. The 
measurement was compared with PBRA calculations 
from the planning system (patient and bolus replaced 
with water phantom). Isodose plots are compared for 
the chest wall and the temple patients in Figures 9a and 
10a, respectively. Regions in which calculated dose ex-
ceeds 10%, measured dose differs by 3%, and distance 
to agreement (DTA) exceeds 0.3 cm are demarcated. 
Only small areas near the superior penumbra of the 
chest wall patient field exceeded that criteria, having a 
99.9% pass rate; the temple intensity modulator had a 
100% pass rate. Also, it should be appreciated that this 
QA test not only validates the intensity modulator, but 
also the electron cutout.
Another way of evaluating the dose comparisons is 
plotting dose difference histograms, which are plotted 
in Figures 9b and 10b for the chest wall and temple, 
respectively. These result show agreement within ap-
proximately (−3%, +5%,) and (−3%, +4%), respectively, 
for calculated dose greater than 80%.
4 |  DISCUSSION
4.1 | Impact potential of IM- BECT
In IM- BECT the purpose of intensity modulation is to 
improve PTV dose homogeneity as compared to BECT, 
as first reported by Kudchadker et al.7 For this report, 
the two patient cases illustrating the IM- BECT tech-
nique were selected based on their having been treated 
with BECT and having hot spots in their PTVs. Results 
showed IM- BECT to improve dose homogeneity in the 
PTV by a modest amount; D90- 10 was reduced from 
7.3% to 6.4% for the chest wall case and 11.0% to 8.4% 
for the temple case, somewhat less than the 14.9% to 
9.2% for the buccal mucosa case of Kudchadker et al.7 
Generally, electron beam therapy offers the potential 
to reduce secondary cancer control probability and 
dose to distal structures, the latter being enhanced by 
using BECT. IM- BECT offers opportunity for improving 
BECT PTV dose homogeneity. Overall, the utility of IM- 
BECT will depend upon how much normal tissue dose/
complication probability and secondary cancer control 
F I G U R E  8  (a) Temple objective 
isointensity map as calculated by p.d 
(b) Pin pattern design resulting from 
segmentation of objective intensity 
map as described in Section 2.2.2. (c) 
PBA- calculated intensity map based on 
pin pattern. (d) Photograph of intensity 
modulator fabricated for the temple 
IM- BECT treatment plan. (- X is medial/
anterior; - Y is inferior)
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probability might be reduced compared to current tech-
niques. This suggests the need for patient studies to 
determine which sites might benefit most from IM- 
BECT as compared to BECT, IMXT, and other current 
techniques.
The primary purpose of the current study was 
to expound on a process of using passive intensity 
modulators for IM- BECT by further describing its 
planning, fabrication, and quality assurance tech-
niques. As with any new technology, research and 
development is an ongoing process, and potential re-
finements of these individual clinical techniques are 
discussed below.
4.2 | Reapplication of IM Operator in IM- 
BECT treatment planning
Following application of the intensity modulation op-
erator and bolus redesign, using an earlier research 
version of the p.d software (with intensity modula-
tor operator, but without island block segmentation), 
Doiron21 showed benefit from one to two or more it-
erations of reapplying the intensity modulation opera-
tor and bolus redesign. The research version of the 
p.d software used in the present study included island 
block segmentation, but did not allow such further itera-
tions. Hence, the IM- BECT plans in the present study 
might not necessarily be optimal, but were suitable for 
illustrating IM- BECT planning, fabrication, and quality 
assurance techniques. Future versions of IM- BECT 
software will include such capability prior to clinical 
release. Also, clinical use might be further improved 
through research and development of methods for si-
multaneous optimization of bolus and intensity modula-
tor design.
4.3 | Quality assurance of 
intensity modulators
The factory QA process verified proper fabrication of 
the intensity modulator, that is, that island blocks are in 
the proper locations with the proper diameters. The lo-
cations were determined using computer software and 
an optical scanned image of the intensity modulator, 
and the diameters were verified manually; however, as 
the number of fabricated intensity modulators increases 
and prior to clinical release, software to determine is-
land block diameters will be implemented.
F I G U R E  9  (a) For the chest wall 
patient, calculated (solid) and measured 
(dashed) isodose plots downstream of 
the intensity modulator at 2.0- cm depth in 
water. Points not meeting the 3% or 3 mm 
criteria are highlighted in black (measured 
> calculated). (b) For the chest wall 
patient, histogram of the dose differences 
between the calculated and measured 
isodose data. Highlighted in black are the 
points receiving <80% of the given dose
F I G U R E  10  (a) For the temple 
patient, calculated (solid) and measured 
(dashed) isodose plots downstream 
of the intensity modulator at 2.0- cm 
depth in water. All points met the 3% or 
3 mm criteria. (b) For the temple patient, 
histogram of the dose differences 
between the calculated and measured 
isodose data. Highlighted in black are the 
points receiving <80% of the given dose
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Regarding the clinical QA process, clinical pass rates 
should be studied using a diode or ion chamber matrix, 
as such measurement techniques are more standard 
and practical than a beam scanning water phantom 
system. Also, a number of intensity modulators should 
be studied to better determine passing criteria and 
rates using current methods or gamma analysis and 
to investigate their dependence on minimum IRF and 
patient site.
4.4 | Accuracy of PBRA dose 
calculation
Small differences between measured and calculated 
doses is expected due to the current PBRA calcula-
tion assuming perfect island block collimation, that is, 
scatter into and from the sides of the block has not 
been modeled. Preliminary data of Hilliard20 and more 
recent ongoing measurements showed PBRA calcu-
lations can underestimate measurements at 0.5 and 
2.0 cm depths by as much as 5% in the energy range 
of 7– 20 MeV for a large array of island blocks that cre-
ate an IRF of 60%. Such extreme modulation is highly 
unlikely for IM- BECT, hence this assumption had little 
impact on the accuracy of the PBRA calculated dose 
in the current study, as illustrated by the QA results. 
However, for other applications, this might not always 
be the case; therefore, scatter into and from the sides 
of the island blocks is being investigated further and in 
the future will be modeled in the PBRA.
4.5 | Clinical Implementation
Clinical implementation of IM- BECT is envisioned as 
an addition to the BECT process, which has been clini-
cally available for over a decade. The BECT process, 
as implemented by .decimal (Sanford, FL), uses an 
external software (p.d) to design the patient- specific 
bolus, which once designed is transferred to the clinic's 
treatment planning system as a structure for use in cal-
culating the final dose plan. In parallel the bolus design 
is transmitted to .decimal for fabrication. The fabricated 
bolus is sent to the clinic, where its construction is typi-
cally verified by performing a dose calculation using a 
CT scan with the fabricated bolus in place. Other steps 
such as collimator fabrication, MU calculations are the 
same as for an electron beam therapy treatment with-
out conformal bolus. This incremental process can be 
completed in a 2– 3 day time frame.
IM- BECT is a BECT treatment with the addition 
of an intensity modulator; however, there are signifi-
cant changes to the process. First, IM- BECT must be 
planned by an electron planning system that can design 
intensity modulators and compute dose for electron 
beams with intensity modulation, a feature unavailable 
in current treatment planning systems. Such a commer-
cial system is currently under development. Because 
intensity modulation is designed in conjunction with 
bolus design, required planning time should have in-
significant increase. Second, the intensity modulator 
requires fabrication, which is done in parallel with bolus 
fabrication, adding no increase to the pretreatment 
time. As the intensity modulator is rigidly embedded in 
the electron cutout, the cutout must be fabricated as 
part of the intensity modulator fabrication process. This 
is consistent with the concept that the cutout is an inten-
sity modulator transmitting a relative electron fluence of 
unity inside and zero outside its aperture. Third, once 
received, QA of the intensity modulator and cutout can 
be performed using the methodology discussed earlier. 
This step could increase the time to treatment by a day. 
To clinically implement IM- BECT, staff competence in 
electron beam therapy, understanding of the IM- BECT 
process and its clinical utility, availability of an IM- 
BECT planning system, and access to a 2D matrix de-
tector like MapCHECK for intensity modulator QA are 
required competencies and equipment.
4.6 | Failure mode and effects analysis 
(FMEA)
As IM- BECT modulates range (energy) and intensity 
versus off- axis position using physical boluses and 
intensity modulators, respectively, it provides a sig-
nificantly advanced electron beam therapy technology, 
which is comparable to advanced x- ray and proton 
therapies. Although QA procedures exist for BECT and 
additional ones are presented here for IM- BECT, both 
modalities could benefit from a study of its workflow 
using FMEA analysis.31 FMEA analyzes have been 
reported for special electron techniques, such as total 
skin electron therapy32 and intraoperative electron 
therapy,33,34 and the IM- BECT workflow process re-
ported here could benefit from such analysis once all 
steps are finalized and an initial commercial product 
becomes clinically available.
5 |  SUMMARY AND 
FUTURE DEVELOPMENT
This work describes and demonstrates for the first 
time techniques comprising a clinical process for in-
tensity modulated bolus electron conformal therapy 
(IM- BECT), which is an expansion of the process for 
bolus electron conformal therapy (BECT). It describes 
how (1) an intensity map operator is integrated into the 
BECT treatment planning process, (2) an intensity map 
is converted (segmented) into a set of island blocks that 
comprise the intensity modulator, (3) the PBRA dose 
algorithm is modified to compute dose in the presence 
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of the intensity modulator, (4) the intensity modulator is 
fabricated, and (5) how quality assurance is performed 
at the factory and the clinic. This process was dem-
onstrated for two patient examples, both previously 
treated using BECT, one a postmastectomy chest wall 
and one a temple.
The demonstration illustrates the feasibility for 
having an efficient, potentially economical method 
for delivering IM- BECT using existing electron beam 
treatment machines. Software for planning IM- BECT, 
which requires modifications to current clinically avail-
able BECT software (p.d) and interfacing it to other 
treatment planning systems, has been produced in a 
research capacity and is currently being further de-
veloped as part of an NIH SBIR grant for technology 
transfer. Also, factory fabrication of patient- specific in-
tensity modulators has been demonstrated, as have 
methods for factory and clinical quality assurance. As 
part of an NIH SBIR grant, improvements to the PBRA 
dose calculation, improvements to the factory quality 
assurance process, and methods for improving effi-
ciency and setting thresholds for clinical quality assur-
ance are being researched and developed. Also, as 
part of the grant and as this technology becomes avail-
able, its clinical utility will be studied, that is, which pa-
tient sites and characteristics might benefit most from 
IM- BECT as compared to existing BECT and IMXT.
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